Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation

Xu, Jiachao; Su, Cunjin; Zhao, Fu-Jun; Ji, Tao; Hu, Duanmin; Shi, Aiming; Pan, Jie; Zhang, Yusong

doi:10.1016/j.bbrc.2018.08.142

Cited by 33 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, knockdown of lncRNA growth arrest specific 5 ( Gas5 ) in melanoma enhanced intracellular ROS via increased superoxide anion and NADPH oxidase 4 (NOX4)-oxidized GSH 153 . In lung cancer cells, the intracellular oxidative stress induced by paclitaxel was attenuated by knockdown of maternally expressed 3 ( Meg3 ), and Meg3 overexpression induced cell death and increased sensitivity to paclitaxel in an ROS-dependent manner 154 . In total, lncRNAs influence ROS metabolism via control of GSH, iron, NRF2 and other factors, and these factors can regulate lncRNAs expression reversely.…”

Section: Introductionmentioning

confidence: 99%

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Zhang

Wang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Cancer progression including proliferation, metastasis, and chemoresistance has become a serious hindrance to cancer therapy. This phenomenon mainly derives from the innate insensitive or acquired resistance of cancer cells to apoptosis. Ferroptosis is a newly discovered mechanism of programmed cell death characterized by peroxidation of the lipid membrane induced by reactive oxygen species. Ferroptosis has been confirmed to eliminate cancer cells in an apoptosis-independent manner, however, the specific regulatory mechanism of ferroptosis is still unknown. The use of ferroptosis for overcoming cancer progression is limited. Noncoding RNAs have been found to play an important roles in cancer. They regulate gene expression to affect biological processes of cancer cells such as proliferation, cell cycle, and cell death. Thus far, the functions of ncRNAs in ferroptosis of cancer cells have been examined, and the specific mechanisms by which noncoding RNAs regulate ferroptosis have been partially discovered. However, there is no summary of ferroptosis associated noncoding RNAs and their functions in different cancer types. In this review, we discuss the roles of ferroptosis-associated noncoding RNAs in detail. Moreover, future work regarding the interaction between noncoding RNAs and ferroptosis is proposed, the possible obstacles are predicted and associated solutions are put forward. This review will deepen our understanding of the relationship between noncoding RNAs and ferroptosis, and provide new insights in targeting noncoding RNAs in ferroptosis associated therapeutic strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Zhang

Wang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…The effective chemotherapeutic drug, paclitaxel (PTX), can increase MEG3, thus promoting A549 cell apoptosis by increasing p53 expression. Further, over-expressed MEG3 can strengthen PTX's anti-tumor activity in A549 cells [171]. DDP can increase miR-425-3p in cells and NSCLC cell-derived exosomes.…”

Section: Discussionmentioning

confidence: 92%

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

Lai

Tang

et al. 2020

IJMS

View full text Add to dashboard Cite

Lung cancer is one of the most malignant cancers around the world, with high morbidity and mortality. Metastasis is the leading cause of lung cancer deaths and treatment failure. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs), two groups of small non-coding RNAs (nc-RNAs), are confirmed to be lung cancer oncogenes or suppressors. Transforming growth factor-β (TGF-β) critically regulates lung cancer metastasis. In this review, we summarize the dual roles of miRNAs and lncRNAs in TGF-β signaling-regulated lung cancer epithelial-mesenchymal transition (EMT), invasion, migration, stemness, and metastasis. In addition, lncRNAs, competing endogenous RNAs (ceRNAs), and circular RNAs (circRNAs) can act as miRNA sponges to suppress miRNAs, thereby mediating TGF-β signaling-regulated lung cancer invasion, migration, and metastasis. Through this review, we hope to cast light on the regulatory mechanisms of miRNAs and lncRNAs in TGF-β signaling-regulated lung cancer metastasis and provide new insights for lung cancer treatment.

show abstract

“…87 Zhou et al found that lncRNA LOC285194 acted as a tumor suppressor in non-small cell lung cancer by regulating p53 and suggested that the lncRNA is involved in regulating the KRAS/BRAF/ SMEK pathway. 88 Zhang et al showed that lncRNA FENDRR inhibited the proliferation, migration, and invasion capacities of non- 91 Key data are summarized in Table 9.…”

Section: Lung Cancermentioning

confidence: 99%

“…In addition, Huang et al demonstrated that lncRNA STXBP5‐AS1 acts as a tumor suppressor in non‐small cell lung cancer by inhibiting cell proliferation, migration, and invasion 90 . Further, Xu et al found that paclitaxel for advanced non‐small cell lung cancer decreased proliferation of such cells by upregulating lncRNA MEG3, which increased the expression of p53 91 . Key data are summarized in Table 9.…”

Section: Therapeutic Activity Of Lncrna In Cancermentioning

confidence: 99%

Therapeutic potential of extracellular vesicle‐associated long noncoding RNA

Born

Harmon

Jay

2020

Bioengineering & Transla Med

View full text Add to dashboard Cite

Both extracellular vesicles (EVs) and long noncoding RNAs (lncRNAs) have been increasingly investigated as biomarkers, pathophysiological mediators, and potential therapeutics. While these two entities have often been studied separately, there are increasing reports of EV-associated lncRNA activity in processes such as oncogenesis as well as tissue repair and regeneration. Given the powerful nature and emerging translational impact of other noncoding RNAs such as microRNA (miRNA) and small interfering RNA, lncRNA therapeutics may represent a new frontier. While EVs are natural vehicles that transport and protect lncRNAs physiologically, they can also be engineered for enhanced cargo loading and therapeutic properties. In this review, we will summarize the activity of lncRNAs relevant to both tissue repair and cancer treatment and discuss the role of EVs in enabling the potential of lncRNA therapeutics. K E Y W O R D S exosomes, extracellular vesicles, lncRNA, microparticles, microvesicles lncRNAs play diverse regulatory roles in normal physiological processes. Thus, delivery of lncRNAs via EVs may help in the treatment Abbreviations: CRCs, colorectal carcinoma cells; EVs, extracellular vesicles; hAD-MSCs, human adipose-derived mesenchymal stem cells; HCAECs, human coronary artery endothelial cells; HCC, hepatocellular carcinoma cell; HDFs, human dermal fibroblasts; HDMECs, human dermal microvascular endothelial cells; lncRNA, long noncoding RNA; miRNA, microRNA; SCCs, squamous carcinoma cells.

show abstract

Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation

Cited by 33 publications

References 22 publications

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

Therapeutic potential of extracellular vesicle‐associated long noncoding RNA

Contact Info

Product

Resources

About